KALA Bio, Inc. (NASDAQ:KALA) ("KALA" or the "Company") today announced that on September 24, 2026, it signed a non-binding letter of intent ("LOI") for the proposed acquisition of 100% of a privately held, U.S.-based management services organization ("MSO") supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform serving clients in all 50 states (the "Target"). Based on unaudited financial information provided by the Target's management, the Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026.